Hepatocellular carcinoma (HCC) is a form of primary liver cancer that begins in the cells of the liver, or hepatocytes. Individuals with hepatitis B, C, cirrhosis, overweight, and hypertension are more likely to develop the illness. Imaging techniques such as ultrasound, MRI, CT scan, and liver biopsy are used to diagnose hepatocellular cancer. Radiation therapy, ablation therapy, chemotherapy, and targeted medication therapy are the most common forms of treatment for hepatocellular cancer. The majority of HCC patients are identified when their liver disease has progressed to the point that they can no longer function. The death rate is nearly equal to the incidence rate due to the condition’s dismal prognosis. As a result, early identification of the cancer is a critical criteria for improving the patient survival with hepatocellular carcinoma, assisting in the growth of the global hepatocellular carcinoma drugs market.
Get Sample Report with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/1596
The rising global prevalence of hepatocellular carcinoma patients is a significant factor driving the global hepatocellular carcinoma drugs market expansion. According to a 2014 study published in the International Journal of Cancer Research and Treatment, HCC is the sixth most prevalent form of cancer and the third leading cause of death globally, with males ranking fifth and women eighth. Moreover, the arrival of new health conditions such as hepatitis B and C viral infections, thyroid disturbances such as diabetes and non-alcoholic fatty liver disease, and exposure to toxins such as alcohol and aflatoxin has been linked to an increased occurrence and death rates of hepatocellular carcinoma.
Clinical improvements, together with regulatory agency approval of new medicines for the treatment of hepatocellular carcinoma, are boosting the global hepatocellular carcinoma drugs market expansion. Regorafenib (Stivarga), a drug made by Bayer HealthCare Pharmaceuticals Inc., was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of patients with hepatocellular carcinoma.
The adverse effects of the medicines, such as anemia, diarrhea, low white blood cell concentration, and pneumonia, are limiting the global hepatocellular carcinoma drugs market’s expansion.
Purchase This Premium Report Here To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/1596
Due to the increased incidence of the illness and the growing number of clinical trials conducted by companies to meet the unmet medical requirements of patients, North America is anticipated to retain a leading position in the global hepatocellular carcinoma drugs market during the forecast period. According to a poll conducted by the Health Science Department at the University of California, Los Angeles (UCLA), hepatocellular carcinoma (HCC) accounts for quarters of all liver cancers in the United States, with an estimated 40,000 Americans afflicted with the disease in 2017 and more than 28,000 deaths.
Due to the increasing number of research and development efforts performed by companies in the area to create effective medicines, Asia Pacific is projected to achieve considerable traction in the global hepatocellular carcinoma drugs market. In February 2017, Daiichi Sankyo, a Japanese drug firm, completed the Phase III research of tivantinib, which is used to treat patients with hepatocellular carcinoma who have failed previous treatments.
The manufacturers are concentrating on strategic partnerships to jointly develop and market immunotherapies for a wide spectrum of malignancies. Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. announced a deal for a strategic partnership in 2014 to effectively integrate and commercialize numerous immunotherapies as single agents and targeted therapy with Opdivo to resolve unmet medical needs of cancer patients in Japan, South Korea, and Taiwan.
Major companies contributing in the global hepatocellular carcinoma drugs market are Bristol-Myers Squibb Company, Merck & Co., Inc., Bayer AG, Amgen Inc., Pfizer Inc., Novartis Pharmaceuticals, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Celgen Corporation, Johnson & Johnson, and AbbVie Inc.
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/1596
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027